ScoreComparison
Why is Alphamab Oncology ?
1
Weak Long Term Fundamental Strength with an average Return on Equity (ROE) of 2.31%
- Poor long term growth as Operating profit has grown by an annual rate 23.73% of over the last 5 years
- Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -19.37
2
With ROE of 12.42%, it has a Expensive valuation with a 4.40 Price to Book Value
- Over the past year, while the stock has generated a return of 8.92%, its profits have risen by 208.3% ; the PEG ratio of the company is 0.2
Real-Time Research ReportHow much should you sell?
- All quantity irrespective of whether you are making profits or losses
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to re-enter? - We will constantly monitor the company and review our call based on new data
Is Alphamab Oncology for you?
High Risk, High Return
Absolute
Risk Adjusted
Volatility
Alphamab Oncology
8.92%
2.76
78.78%
Hang Seng Hong Kong
8.25%
0.41
19.93%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
439.98%
EBIT Growth (5y)
23.73%
EBIT to Interest (avg)
-19.37
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.76
Sales to Capital Employed (avg)
0.16
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
5.79%
ROE (avg)
2.31%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
35
Industry P/E
Price to Book Value
4.40
EV to EBIT
36.43
EV to EBITDA
26.44
EV to Capital Employed
14.05
EV to Sales
8.75
PEG Ratio
0.17
Dividend Yield
NA
ROCE (Latest)
38.57%
ROE (Latest)
12.42%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bullish
Moving Averages
Mildly Bearish (Daily)
KST
Bearish
Bullish
Dow Theory
Mildly Bullish
Mildly Bearish
OBV
Mildly Bearish
No Trend
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend13What is working for the Company
ROCE(HY)
Highest at 13.34%
NET SALES(Q)
At HKD 343.12 MM has Grown at 82.44%
PRE-TAX PROFIT(Q)
At HKD 23.17 MM has Grown at 147.64%
NET PROFIT(Q)
At HKD 23.17 MM has Grown at 147.64%
RAW MATERIAL COST(Y)
Fallen by -55.52% (YoY
CASH AND EQV(HY)
Highest at HKD 1,801.92 MM
DEBTORS TURNOVER RATIO(HY)
Highest at 23.53 times
-1What is not working for the Company
NO KEY NEGATIVE TRIGGERS
Here's what is working for Alphamab Oncology
Net Sales
At HKD 343.12 MM has Grown at 82.44%
Year on Year (YoY)MOJO Watch
Near term sales trend is very positive
Net Sales (HKD MM)
Pre-Tax Profit
At HKD 23.17 MM has Grown at 147.64%
Year on Year (YoY)MOJO Watch
Near term Pre-Tax Profit trend is very positive
Pre-Tax Profit (HKD MM)
Net Profit
At HKD 23.17 MM has Grown at 147.64%
Year on Year (YoY)MOJO Watch
Near term Net Profit trend is very positive
Net Profit (HKD MM)
Cash and Eqv
Highest at HKD 1,801.92 MM
in the last six Semi-Annual periodsMOJO Watch
Short Term liquidity is improving
Cash and Cash Equivalents
Debtors Turnover Ratio
Highest at 23.53 times
in the last five Semi-Annual periodsMOJO Watch
Company has been able to sell its Debtors faster
Debtors Turnover Ratio
Raw Material Cost
Fallen by -55.52% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for Alphamab Oncology
Non Operating Income
Highest at HKD 1.15 MM
in the last five periodsMOJO Watch
Increased income from non business activities may not be sustainable
Non Operating income
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
